Omeros Corporation

NASDAQ:OMER

Biotechnology

Healthcare
$13.92 +4.46%

+$0.43 today

Market cap
$1.01B
Beta
2.53
P/E (TTM)
8.4
EPS (TTM)
$1.20
52W Low $2.95High $17.65

Volume 5.34M

Average 1.55M

Returns on capital

Omeros Corporation management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

2.8%

avg 244.0%

ROIC

-45.3%

avg -86.6%

ROA

-1.0%

avg -61.4%

Analysis

ROE is currently the strongest return metric at 2.8% versus its period average of 244.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Gregory A. Demopulos

Co-Founder, Chairman, Chief Executive Officer & PresidentUSD 1.97M67——

Peter Cancelmo

Vice President, General Counsel & Corporate SecretaryUSD 665.45K47——

David J. Borges

Vice President of Finance, Chief Accounting Officer & TreasurerUSD 443.78K610<0.01%

Catherine A. Melfi

Chief Regulatory Officer & Vice President of Regulatory Affairs and Quality Systems—67——

George A. Gaitanaris

Chief Scientific Officer & Vice President of Science—69——

Peter W. Williams

Vice President of Human Resources—58——

William E. Woodman

Vice President & Chief Commercial Officer————

Pamela Pierce Palmer

Co-Founder—63——

David W. Ghesquiere

Vice President & Chief Business Development Officer—59——

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 23, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

13

$2.83M

Net Transaction Value

−$2.83M

Net selling

Most Active

Borges David J.

6 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Sep 23, 26

Borges David J.

Direct

Sell$209.5K
Aug 31, 26

Cancelmo Peter B

Direct

Sell$463.5K
Aug 28, 26

Cancelmo Peter B

Direct

Sell$466.1K
Aug 27, 26

HANISH ARNOLD C

Direct

Sell$94.4K
Aug 27, 26

HANISH ARNOLD C

Direct

Sell$95.1K
Aug 26, 26

HANISH ARNOLD C

Direct

Sell$92.6K
Aug 24, 26

Borges David J.

Direct

Sell$17.3K
Aug 21, 26

Borges David J.

Direct

Sell$189.5K
Aug 20, 26

Cable Thomas J.

Direct

Sell$276.8K
Aug 13, 26

Borges David J.

Direct

Sell$84.8K

1–10 of 13

Summary

Insiders reported 0 buys worth $0.00 and 13 sells worth $2.83M over the last 12 months. That adds up to net selling of $2.83M. Borges David J. was the most active insider with 6 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/AN/A
N/A1 analysts
Net IncomeN/AN/AN/A
N/A1 analysts
EBITN/AN/AN/A
N/A1 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Omeros Corporation compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about OMER's management, answered from reported figures.

Who manages OMER?

Omeros Corporation (OMER) lists 9 active executives. The top listed executive is Catherine A. Melfi, Chief Regulatory Officer & Vice President of Regulatory Affairs and Quality Systems.

Are OMER insiders buying or selling?

Recent insider activity shows net buying of $43.28M.